I Mab Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

I Mab Stock Summary

I Mab competes with BeiGene, Krystal Biotech, Immunovant, Foghorn Therapeutics, and Shattuck Labs. I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 378 people.

I Mab Key Financial Ratios

I Mab Key Balance Sheet Accounts

I Mab Key Cash Accounts

IMAB Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining I Mab's current stock value. Our valuation model uses many indicators to compare I Mab value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across I Mab competition to find correlations between indicators driving I Mab's intrinsic value. More Info.I Mab is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, I Mab's Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the I Mab's earnings, one of the primary drivers of an investment's value.

I Mab Systematic Risk

Today, most investors in I Mab Stock are looking for potential investment opportunities by analyzing not only static indicators but also various I Mab's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of I Mab growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of I Mab help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of I Mab. We use our internally-developed statistical techniques to arrive at the intrinsic value of I Mab based on widely used predictive technical indicators. In general, we focus on analyzing IMAB Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build I Mab's daily price indicators and compare them against related drivers.

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.